Investor Education Series | HSTECH vs HSBIO: Two Pathways into Hong Kong’s Innovation Story
Innovation remains one of the most compelling themes for investors, from AI and semiconductors to healthcare. In Hong Kong, this story is told through different indexes, each offering a distinct way to participate in long‑term growth using convenient investment products.
Two of the most widely followed innovation benchmarks are the Hang Seng TECH Index (HSTECH) and the Hang Seng Biotech Index (HSBIO). While both sit under the broad innovation umbrella, they reflect very different growth drivers and risk profiles. Let’s break down what makes each of them tick.
HSTECH: Scale and economic cycles
Think of HSTECH as the home for 30 leading tech companies listed in Hong Kong. This index tracks the performance of internet platforms, e‑commerce giants, cloud and digital services providers, and semiconductor-related businesses.
These companies tend to have established products, steady revenue streams and massive customer bases. As a result, HSTECH often moves in line with broader economic conditions and earnings expectations.
Market sentiment, policy developments and changes in growth outlook can all influence performance. For investors, the index represents exposure to relatively mature innovation – businesses that are scaling existing technologies and monetising them across large user bases.
HSBIO: Science and breakthroughs
HSBIO also consists of 30 constituents, but its focus is different. This index captures the pioneers in biotechnology and healthcare, including drug developers, biopharmaceutical firms and medical technology innovators. Here, progress doesn't just rely on consumer spending; it heavily depends on research outcomes, clinical milestones and regulatory approvals.
This means price movements can be more company‑specific. A successful clinical trial for a single drug can significantly impact a company's valuation.
While biotechnology indices are often perceived as early‑stage, here are the facts about HSBIO: As of the end of May 2026,
✅ Only about 4.2% of HSBIO’s weight comes from pre‑revenue companies1
✅ The remaining 95.8% made up of revenue‑generating names1
This reflects strengthening fundamentals and growing global recognition of China‑originated innovation.
Understanding the exposure
For retail investors, the key is understanding what each index represents. HSTECH offers exposure to established tech leaders tied more closely to economic cycles, while HSBIO provides access to the potential upside and risks of medical innovation.
Both indexes can be accessed through shares of their constituent companies, exchange‑traded funds and structured products available on HKEX. Investors should consider their own risk tolerance, time horizon and which innovation story aligns best with their investment objectives.
Glossary
|
Constituents |
The individual stocks included in an index. |
|
Exchange Traded Fund (ETF) |
A fund that trades on the stock exchange and aims to track the performance of an index or underlying asset. |
|
Index weight |
The proportion that each stock contributes to an index, usually based on its market size. |
|
Pre‑revenue company |
A company that has not yet started generating revenue, often because its products or services are still under development. |
|
Structured products |
Investment products with returns linked to an underlying asset or index, where pay‑offs are subject to certain price conditions and terms. They can be more complex and may not be suitable for all investors. |
Note:
1. Source: HKEX
Disclaimer:
The content of the website is published by ZA Bank Limited (“ZA Bank”) for reference only. You should not make any decision solely based on the article. You are not allowed to copy, sell, transmit, broadcast, modify or disseminate this article (including electronic, printed, or other media now known or hereafter developed), or in any way for commercial or public purposes without prior consent from ZA Bank.
If you have any enquiries about the content of this article, you should seek professional advice from an independent person. We are under no obligation to post to you any further updates to the content. Such information may change from time to time without notice. Such information does not constitute an offer, solicitation or recommendation of an offer or any tax, financial, investment, legal, and professional advice to you. ZA Bank is not liable for any problems, damages, losses, or liabilities arising directly or indirectly from the information provided herein under any circumstances.